Glutamate decarboxylase autoimmunity and growth hormone secretion in type I diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 46, Issue 4, 1997, Pages 382-387

  Giustina, Andrea ^a   Desenzani, Paolo ^b   Perini, Paola ^b   Bazzigaluppi, Elena ^b   Bodini, Corrado ^b   Bossoni, Simonetta ^b   Poiesi, Claudio ^b   Wehrenberg, William B ^b   Bosi, Emanuele ^b  

^a SPEDALI CIVILI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PYRIDOSTIGMINE; SOMATOSTATIN;

ADULT; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; FEMALE; GABAERGIC SYSTEM; GROWTH HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL;

EID: 0030900560     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90052-4     Document Type: Article

References (40)

1. Lundbaek K, Christensen NJ, Jensen VA, et al: Diabetes, diabetic angiopathy, and growth hormone. Lancet 2:131-133, 1970
2. Osterby R, Seyer-Hansen K, Gundersen HJG, et al: Growth hormone enhances basement membrane thickening in experimental diabetes. Diabetologia 15:487-489, 1978
3. Hayford JT, Danney MM, Hendrix JA, et al: Integrated concentration of growth hormone in juvenile-onset diabetes. Diabetes 29:391-398, 1980
4. Arias P, Kerner W, De La Fuente A, et al: Abnormal growth hormone levels in insulin dependent diabetic patients under continuous subcutaneous insulin infusion and intensified conventional treatment. Acta Endocrinol (Copenh) 107:250-255, 1984
5. Asplin CM, Faria ACS, Carlsen EC, et al: Alterations in the pulsatile mode of growth hormone release in men and women with insulin dependent diabetes mellitus. J Clin Endocrinol Metab 69:239-245, 1989
6. Krassowski J, Felberg JP, Rogala H, et al: Exaggerated growth hormone response to growth hormone releasing hormone in type 1 diabetes mellitus. Acta Endocrinol (Copenh) 117:225-229, 1988
7. Pietschmann P, Schernthaner G, Prskavec F, et al: No evidence for increased growth hormone response to growth hormone releasing hormone in patients with diabetic retinopathy. Diabetes 36:159-162, 1987
8. Giustina A, Bossoni S, Cimino A, et al: Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH releasing hormone stimulated GH secretion. J Clin Endocrinol Metab 71:1486-1490, 1990
9. Wehrenberg WB, Wiviott SD, Voltz DM, et al: Pyridostigminemediated growth hormone release: Evidence for somatostatin involvement. Endocrinology 130:1445-1450, 1992
10. Ismail IS, Scanlon MF, Peters JR: Cholinergic control of growth hormone (GH) response to GH-releasing hormone in insulin dependent diabetics: Evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback. Clin Endocrinol (Oxf) 38:149-157, 1993
11. Press M, Caprio S, Tamborlane WV, et al: Pituitary response to growth hormone-releasing hormone in IDDM: Abnormal responses to insulin and hyperglycemia. Diabetes 41:17-21, 1992
12. Eisenbarth GS: Type I diabetes mellitus: A chronic autoimmune disease. N Engl J Med 314:1360-1368, 1986
13. Gale EF: The bacterial amino acid decarboxylases. Adv Enzymol 6:1-32, 1946
14. Baekkeskov S, Aanstoot HJ, Christgau S, et al: Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347:151-156, 1990
15. Atkinson MA, Kaufman DL, Campbell L, et al: Response of peripheral blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 339:458-459, 1992
16. Bosi E, Bonifacio E, Bottazzo GF: Autoantigens in IDDM. Diabetes Rev 1:204-214, 1993
17. Steardo L, Iovino M, Monteleone P, et al: Pharmacological evidence for a dual GABAergic regulation of growth hormone release in humans. Life Sci 38:979-985, 1986
18. McCann SM, Vijayan E, Negro-Vilar A, et al: Gamma aminobutyric acid (GABA), a modulator of anterior pituitary hormone secretion by hypothalamic and pituitary action. Psychoneuroendocrinology 9:97-106, 1984
19. Cavagnini F, Invitti C, Di Landro A, et al: Effects of a GABA derivative, baclofen, on growth hormone and prolactin secretion in man. J Clin Endocrinol Metab 45:579-584, 1977
20. Coiro V, Volpi R, Maffei ML, et al: Opioid modulation of the gamma-aminobutyric acid-controlled inhibition of exercise-stimulated growth hormone and prolactin secretion in normal men. Eur J Endocrinol 131:50-55, 1994
21. Bottazzo GF, Florin-Christensen A, Doniach D: Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiency. Lancet 2:1279-1283, 1974
22. Rabin DU, Pleasic SM, Palmer-Crocker R, et al: Cloning and expression of IDDM specific human autoantigens. Diabetes 41:183-186, 1992
23. Bonifacio E, Genovese S, Braghi S, et al: Islet autoantibody markers in insulin dependent diabetes: Risk assessment strategies yielding high sensitivity. Diabetologia 38:816-822, 1995
24. Bonifacio E, Bingley PJ, Shattock M, et al: Quantification of islet cell antibodies and prediction of insulin-dependent diabetes. Lancet 335:147-149, 1990
25. Rowley MJ, Mackay IR, Chen QY, et al: Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 41:548-551, 1992
26. Hansen AP: Abnormal serum growth hormone response to exercise in juvenile diabetics. Clin Invest 49:1476-1478, 1970
27. Holland PM, Landers MB, Lebovitz HE, et al: Levodopastimulated growth hormone secretion and diabetic retinopathy. Am J Ophthalmol 82:612-618, 1976
28. Cremer GM, Molnar GD, Taylor WF, et al: Growth hormone release in unstable diabetes. Tests with saline, arginine, glucagon and epinephrine. Acta Diabetol Lat 10:1216-1221, 1973
29. William G, Ghatei MA, Diani AR, et al: Reduced hypothalamic somatostatin and neuropeptide Y concentrations in the spontaneouslydiabetic Chinese hamster. Horm Metab Res 20:668-670, 1988
30. Giustina A, Licini M, Schettino M, et al: Physiological role of galanin in the regulation of anterior pituitary function in humans. Am J Physiol 266:E57-E61, 1994
31. McLennan H, Miller JJ: Gamma-aminobutyric acid and inhibition in the septal nuclei of the rat. J Physiol 237:625-633, 1974
32. Giustina A, Bossoni S, Bodini C, et al: Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. J Clin Endocrinol Metab 74:1301-1305, 1992
33. Giustina A, Bresciani E, Tassi C, et al: Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type 2 diabetic patients. Metabolism 43:893-898, 1994
34. Giustina A, Wehrenberg WB: Growth hormone neuroregulation in diabetes mellitus. Trends Endocrinol Metab 5:73-78, 1994
35. Solimena M, Folli F, Aparisi R, et al: Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322:1555-1560, 1990
36. Massara F, Ghigo E, Demislis K, et al: Cholinergic involvement in the growth hormone-releasing hormone induced growth hormone release. Studies in normal and acromegalic subjects. Neuroendocrinology 43:670-675, 1986
37. Giustina A, Girelli A, Doga M, et al: Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone secretion in normal man. J Clin Endocrinol Metab 71:580-584, 1990
38. Van der Zee EA, Luiten PGM: Cholinergic and GABAergic neurons in the rat medial septum express muscarinic acetylcholine receptors. Brain Res 652:263-272, 1994
39. Giustina A, Licini M, Bussi AR, et al: Effects of sex and age on the growth hormone response to galanin in healthy human subjects. J Clin Endocrinol Metab 76:1369-1372, 1993
40. Arvat E, Cappa M, Casanueva FF, et al: Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women. J Clin Endocrinol Metab 76:374-377, 1993